Seeing Is Believing
Currently out of the existing stock ratings of Etzer Darout, 93 are a BUY (72.09%), 36 are a HOLD (27.91%).
Analyst Etzer Darout, currently employed at BMO, carries an average stock price target met ratio of 48.43% that have a potential upside of 42.61% achieved within 115 days.
Etzer Darout’s has documented 250 price targets and ratings displayed on 28 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TERN, Terns Pharmaceuticals at 13-May-2025.
Analyst best performing recommendations are on FPRX (FIVE PRIME THERAPEUTICS).
The best stock recommendation documented was for MGNX (MACROGENICS) at 7/11/2022. The price target of $4 was fulfilled within 2 days with a profit of $0.45 (12.68%) receiving and performance score of 63.38.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$10
$6.39 (177.01%)
$10
28 days ago
(29-May-2025)
0/4 (0%)
$5.81 (138.66%)
Buy
$6
$2.39 (66.20%)
$6
10 months 10 days ago
(16-Aug-2024)
2/4 (50%)
$2.4 (66.67%)
200
Buy
$8
$4.39 (121.61%)
$8
1 years 2 months 2 days ago
(24-Apr-2024)
1/6 (16.67%)
$5.55 (226.53%)
720
Hold
2 years 11 months 19 days ago
(07-Jul-2022)
0/2 (0%)
$17.96 (178.88%)
Buy
$11
$8.42 (326.36%)
$14
3 years 11 months 27 days ago
(30-Jun-2021)
0/2 (0%)
$6.82 (124.75%)
Which stock is Etzer Darout is most bullish on?
Which stock is Etzer Darout is most reserved on?
What Year was the first public recommendation made by Etzer Darout?